March 2016, Volume 2, Issue 3

March 2016

Volume 2, Issue 3

This issue features a conversation with hematologist/oncologists who have also been diagnosed with blood disorders themselves, as well as a look at how access to generic medications is becoming more difficult.

Table of Contents

March 2016

Letter From a Cleveland Jail to the ABIM: MOC Madness

Tuesday, March 1st, 2016
American Board of Internal Medicine Philadelphia, PA March 2016 Dear ABIM, Got your last email. Are you just not that into me anymore? There it sat, an unsightly wart amidst...

Speaking the Same Language

Tuesday, March 1st, 2016
Dear Dr. Sekeres: I greatly enjoyed reading your clever and humorous article on gender-neutral pronouns and other language usage . I write a fair amount,...

March 2016

Knudson Award in Cancer Genetics, IMF Announces New Medical Liaison, and more

Tuesday, March 1st, 2016
Paul Ichiro Terasaki, PhD (1929-2016)  Professor Terasaki passed away on January 25, 2016. Prof. Terasaki was a philanthropist and pioneer in organ transplant medicine who invented...

ASH Calls on Congress to Help Address the Burden of Sickle Cell Disease

Tuesday, March 1st, 2016
ASH is in the midst of a multifaceted initiative to identify the highest priority actions needed to improve outcomes for individuals with sickle cell...

March 2016

Pulling Back the Curtain: Fred Schiffman, MD

Tuesday, March 1st, 2016
What was your first job? One of my early jobs was as a waiter at Camp Laurelwood, a summer camp where my parents worked. I...

Walking a Mile in Their Shoes: How Does It Feel to Be Both a...

Tuesday, March 1st, 2016
What happens when a physician becomes a patient – forced to view the health-care community through a different lens? Some physicians may have difficulty...

March 2016

Understanding Mantle Cell Lymphoma

Tuesday, March 1st, 2016
Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Mantle cell lymphoma...

Would you recommend a bone marrow biopsy to complete staging and would you give...

Tuesday, March 1st, 2016
This month, Ann LaCasce, MD, weighs in about recommending a bone marrow biopsy and whether or not to give G-CSF.A 44-year-old male with no...

March 2016

Venetoclax Receives Priority Review for CLL

Tuesday, March 1st, 2016
The U.S. FDA granted breakthrough therapy designation for the investigational drug venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory CLL. The...

FDA Revises Golimumab Label to Reflect Lymphoma and Leukemia Risk

Tuesday, March 1st, 2016
The U.S. FDA revised the labeling of warnings and precautions for golimumab to reflect safety information regarding the incidence of lymphoma and leukemia among...

FDA Approves Expanded Indication for Ofatumumab

Tuesday, March 1st, 2016
The U.S. FDA approved ofatumumab, an anti-CD20 monoclonal antibody, as maintenance therapy for patients with chronic lymphocytic leukemia (CLL) who have achieved complete or...

FDA Places Pacritinib on Full Clinical Hold

Tuesday, March 1st, 2016
The U.S. Food and Drug Administration (FDA) pulled the investigational new drug application for the JAK2 inhibitor pacritinib, halting the ongoing PERSIST-1 and PERSIST-2...

The Cancer Moonshot 2020 Program to Bring Together Researchers, Drugmakers

Tuesday, March 1st, 2016
During the last State of the Union address of his administration, President Obama announced the Cancer Moonshot 2020 initiative, which focuses on finding potential...

Avoiding Heparin: The First Step to Preventing HIT and HITT

Tuesday, March 1st, 2016
Use of an “Avoid-Heparin Initiative” resulted in a dramatic reduction in the burden of heparin-induced thrombocytopenia (HIT) and associated costs, according to a report...

For Patients with Cancer and VTE, Apixaban Associated with Similar Outcomes, Less Bleeding Than...

Tuesday, March 1st, 2016
Patients with cancer are predisposed to developing venous thromboembolism (VTE). While a standard treatment for VTE is the vitamin K antagonist warfarin, high rates...

Access to and Costs of Generic Medications in the United States: A Perspective

Tuesday, March 1st, 2016
Between 2004 and 2013, the broader availability of generic drugs saved the U.S. health-care system nearly $1.5 trillion. However, a number of issues, including...

Should ATG Be Added to Myeloablative Regimens for Hematopoietic Cell Transplantation?

Tuesday, March 1st, 2016
Hematopoietic cell transplantation (HCT) is used to treat a wide range of hematologic malignancies. One anticipated complication is graft-versus-host disease (GVHD) – a condition...

Genetic Mutations May Impact Effectiveness of Ponatinib in Patients with CML

Tuesday, March 1st, 2016
Although progress has been made in increasing the treatment options available to patients with chronic myeloid leukemia (CML), many patients still relapse – most...

Dexamethasone Versus Prednisone in Pediatric Patients with ALL

Tuesday, March 1st, 2016
Pediatric patients with acute lymphocytic leukemia (ALL) often receive induction therapy that includes the glucocorticoid prednisone; however, research has shown that dexamethasone may have...

Ibrutinib Leads to Better Overall and Progression-Free Survival Than Chlorambucil in Older Patients with...

Tuesday, March 1st, 2016
Chronic lymphocytic leukemia (CLL) is a disease of older adults, many of whom have other medical problems in addition to their cancer. Chlorambucil is...

March 2016

SHARE